en
Scientific article
French

Pédiatrie Vaccin conjugué contre les pneumocoques : quel bilan quatre ans après son introduction ?

Published inRevue médicale suisse, vol. 1, no. 2, p. 142,144,146-147
Publication date2005
Abstract

Considerable morbidity and mortality are related to pneumococcal disease predominantly in high risk populations: infants and young children, the elderly and the immunocompromised. A recent heptavalent conjugate anti-pneumococcal vaccine, introduced in the routine immunization program in the United States in 2001, has been shown to be spectacularly effective in the prevention of invasive disease in the very young in contrast to the pre-existing polysaccharide vaccine. As a consequence, horizontal transmission throughout the community is decreased with a reduction in disease rates in non-vaccinated adults. Finally the conjugate vaccine also provides an effective tool for reduction of drug-resistant pneumococcal strains. A review of the existing anti-pneumococcal vaccines, their direct and indirect effects and their recommended use in Switzerland.

Keywords
  • Child, Preschool
  • Humans
  • Infant
  • Meningococcal Vaccines
  • Pneumococcal Infections/prevention & control
  • Pneumococcal Vaccines
  • Time Factors
  • Vaccines, Conjugate
Citation (ISO format)
MYERS, Catherine Jayne, GERVAIX, Alain. Pédiatrie Vaccin conjugué contre les pneumocoques : quel bilan quatre ans après son introduction ? In: Revue médicale suisse, 2005, vol. 1, n° 2, p. 142,144,146–147.
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1660-9379
430views
1downloads

Technical informations

Creation03/25/2015 3:23:00 PM
First validation03/25/2015 3:23:00 PM
Update time03/14/2023 11:03:40 PM
Status update03/14/2023 11:03:39 PM
Last indexation01/16/2024 5:28:37 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack